Capital that moves you forward.
Accessing capital to scale into the US shouldn’t be so difficult.
So we created a network of US angels and funds that appreciate the value of EU and ANZ companies in the life sciences—and bring more than just a checkbook.
Mission
Neither dealflow nor access to investors should be gatekept. Instead, the right opportunities for the right investors—with the due diligence that shares what resources a company needs to maximize their changes of success—lets everyone win.
Thesis
B2B companies in healthcare from outside the US with external clinical and technical validation, ready to enter the US within 6 months. Particular interests in cardiology, in vitro diagnostics, diagnostic imaging, oncology, and women’s health.
Size
$1-3.5M USD is our sweet spot, with recommended networks and funds for above and below this amount. Open to most vehicles with reasonable terms at a grounded valuation.
Apply
Companies can apply on a rolling basis and are generally scheduled for an interview within three weeks.
Interview
We speak with each team to better understand their mission and the next stage of their business.
Process
Down-Selection
We conduct light due diligence and select companies based on potential and fit with our investment network.
The application fee of $150 includes specific feedback on the pitch and is non-refundable.
If your investment narrative requires polishing, we can help as part of our strategic services arm.
Syndication
Selected companies are presented to the investment network. With enough interest, we conduct due diligence.
Deal Memo
Due diligence includes commercial partners and focuses on risks in scaling, concluding in a deal memo.
Contact us
Venture Atlas labs© 2024 | All rights reserved | Privacy Policy